1. Home
  2. FUSB vs BNR Comparison

FUSB vs BNR Comparison

Compare FUSB & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First US Bancshares Inc.

FUSB

First US Bancshares Inc.

HOLD

Current Price

$16.49

Market Cap

91.4M

Sector

Finance

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$10.44

Market Cap

94.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUSB
BNR
Founded
1952
2014
Country
United States
China
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.4M
94.4M
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
FUSB
BNR
Price
$16.49
$10.44
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
34.3K
4.1K
Earning Date
04-29-2026
06-05-2026
Dividend Yield
1.72%
N/A
EPS Growth
N/A
N/A
EPS
0.64
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$111.65
Revenue Next Year
N/A
N/A
P/E Ratio
$25.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.81
$6.79
52 Week High
$16.99
$41.72

Technical Indicators

Market Signals
Indicator
FUSB
BNR
Relative Strength Index (RSI) 50.20 51.89
Support Level $15.75 $8.69
Resistance Level $16.88 $10.00
Average True Range (ATR) 0.22 0.78
MACD -0.01 0.09
Stochastic Oscillator 62.32 40.24

Price Performance

Historical Comparison
FUSB
BNR

About FUSB First US Bancshares Inc.

First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement accounts, and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

Share on Social Networks: